Udaya Kompella
Concepts (725)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 39 | 2021 | 365 | 7.610 |
Why?
| | Nanoparticles | 33 | 2022 | 481 | 4.630 |
Why?
| | Retina | 27 | 2020 | 298 | 4.470 |
Why?
| | Eye Diseases | 11 | 2021 | 87 | 3.150 |
Why?
| | Sulfonamides | 17 | 2017 | 513 | 3.120 |
Why?
| | Choroid | 14 | 2020 | 62 | 2.760 |
Why?
| | Pyrazoles | 14 | 2014 | 423 | 2.410 |
Why?
| | Eye | 12 | 2017 | 108 | 2.400 |
Why?
| | Triptorelin Pamoate | 14 | 2009 | 19 | 2.170 |
Why?
| | Drug Carriers | 14 | 2019 | 128 | 2.160 |
Why?
| | Vascular Endothelial Growth Factor A | 24 | 2017 | 545 | 2.140 |
Why?
| | Ophthalmic Solutions | 12 | 2025 | 75 | 2.130 |
Why?
| | Polyglycolic Acid | 16 | 2015 | 43 | 2.030 |
Why?
| | Budesonide | 9 | 2020 | 89 | 1.990 |
Why?
| | Lactic Acid | 17 | 2015 | 305 | 1.960 |
Why?
| | Delayed-Action Preparations | 17 | 2020 | 181 | 1.910 |
Why?
| | Pharmaceutical Preparations | 8 | 2022 | 179 | 1.750 |
Why?
| | Pigment Epithelium of Eye | 11 | 2012 | 35 | 1.710 |
Why?
| | Gene Transfer Techniques | 8 | 2014 | 170 | 1.690 |
Why?
| | Sclera | 9 | 2012 | 36 | 1.660 |
Why?
| | Animals | 118 | 2025 | 36940 | 1.610 |
Why?
| | Diabetes Mellitus, Experimental | 9 | 2018 | 195 | 1.580 |
Why?
| | Diabetic Retinopathy | 8 | 2018 | 189 | 1.570 |
Why?
| | Particle Size | 16 | 2020 | 394 | 1.540 |
Why?
| | Conjunctiva | 14 | 2009 | 51 | 1.400 |
Why?
| | Rabbits | 28 | 2022 | 794 | 1.390 |
Why?
| | Enzyme Inhibitors | 10 | 2011 | 840 | 1.340 |
Why?
| | Retinal Pigment Epithelium | 7 | 2013 | 77 | 1.330 |
Why?
| | Nanostructures | 4 | 2019 | 107 | 1.320 |
Why?
| | Blood-Retinal Barrier | 6 | 2013 | 15 | 1.320 |
Why?
| | Tandem Mass Spectrometry | 8 | 2022 | 532 | 1.290 |
Why?
| | Sulfones | 6 | 2012 | 110 | 1.260 |
Why?
| | Vitreous Body | 13 | 2020 | 110 | 1.260 |
Why?
| | Dexamethasone | 4 | 2020 | 368 | 1.250 |
Why?
| | Cyclooxygenase Inhibitors | 6 | 2008 | 79 | 1.240 |
Why?
| | Rats | 34 | 2020 | 5647 | 1.230 |
Why?
| | Photosensitizing Agents | 2 | 2025 | 41 | 1.200 |
Why?
| | Drug Compounding | 6 | 2020 | 101 | 1.190 |
Why?
| | Melanins | 4 | 2012 | 18 | 1.180 |
Why?
| | Capillary Permeability | 6 | 2011 | 145 | 1.170 |
Why?
| | Rats, Sprague-Dawley | 26 | 2020 | 2486 | 1.160 |
Why?
| | Glucocorticoids | 7 | 2021 | 594 | 1.090 |
Why?
| | Anti-Inflammatory Agents | 7 | 2020 | 496 | 1.090 |
Why?
| | Polymers | 8 | 2013 | 490 | 1.080 |
Why?
| | Cattle | 18 | 2021 | 984 | 1.070 |
Why?
| | Receptors, LHRH | 5 | 2009 | 14 | 1.040 |
Why?
| | Anti-Infective Agents | 2 | 2025 | 255 | 1.040 |
Why?
| | Aldehyde Reductase | 5 | 2007 | 29 | 1.020 |
Why?
| | Glycine | 6 | 2009 | 176 | 1.020 |
Why?
| | Photochemotherapy | 2 | 2025 | 44 | 0.990 |
Why?
| | Nanotechnology | 5 | 2019 | 125 | 0.970 |
Why?
| | Cornea | 10 | 2015 | 138 | 0.970 |
Why?
| | Rose Bengal | 1 | 2025 | 1 | 0.960 |
Why?
| | RNA, Small Interfering | 5 | 2017 | 622 | 0.960 |
Why?
| | Nasal Mucosa | 6 | 2009 | 107 | 0.950 |
Why?
| | Keratitis | 1 | 2025 | 15 | 0.950 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 2 | 0.940 |
Why?
| | Blepharitis | 1 | 2025 | 5 | 0.930 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 6 | 2012 | 350 | 0.930 |
Why?
| | Mite Infestations | 1 | 2025 | 8 | 0.930 |
Why?
| | Celecoxib | 14 | 2014 | 39 | 0.920 |
Why?
| | Intercellular Signaling Peptides and Proteins | 5 | 2013 | 382 | 0.910 |
Why?
| | Naphthalenes | 1 | 2025 | 60 | 0.900 |
Why?
| | Angiogenesis Inhibitors | 8 | 2017 | 229 | 0.890 |
Why?
| | alpha-Crystallin B Chain | 2 | 2022 | 24 | 0.880 |
Why?
| | Epithelial Cells | 8 | 2016 | 1096 | 0.860 |
Why?
| | Retinal Degeneration | 3 | 2020 | 38 | 0.850 |
Why?
| | Dendrimers | 4 | 2012 | 18 | 0.840 |
Why?
| | Endothelial Growth Factors | 5 | 2003 | 64 | 0.820 |
Why?
| | Chromatography, Liquid | 7 | 2022 | 433 | 0.820 |
Why?
| | Lymphokines | 5 | 2003 | 131 | 0.810 |
Why?
| | Gonadotropin-Releasing Hormone | 5 | 2006 | 212 | 0.790 |
Why?
| | Cyprinidae | 1 | 2022 | 21 | 0.790 |
Why?
| | Cyclooxygenase 2 Inhibitors | 6 | 2014 | 21 | 0.790 |
Why?
| | Sotalol | 1 | 2022 | 6 | 0.780 |
Why?
| | Intraocular Pressure | 4 | 2020 | 307 | 0.780 |
Why?
| | Tomography, Optical Coherence | 2 | 2021 | 213 | 0.780 |
Why?
| | Choroidal Neovascularization | 6 | 2017 | 56 | 0.780 |
Why?
| | Administration, Topical | 11 | 2020 | 151 | 0.770 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.750 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2012 | 30 | 0.740 |
Why?
| | Awards and Prizes | 1 | 2022 | 67 | 0.740 |
Why?
| | Ophthalmoscopes | 1 | 2021 | 3 | 0.730 |
Why?
| | Tissue Distribution | 10 | 2019 | 332 | 0.730 |
Why?
| | Viscosity | 2 | 2020 | 92 | 0.730 |
Why?
| | Neuroprotective Agents | 1 | 2022 | 131 | 0.720 |
Why?
| | Glaucoma | 4 | 2020 | 237 | 0.710 |
Why?
| | Administration, Ophthalmic | 8 | 2021 | 15 | 0.710 |
Why?
| | Water | 3 | 2019 | 460 | 0.670 |
Why?
| | Peptides | 5 | 2022 | 985 | 0.660 |
Why?
| | Lens, Crystalline | 4 | 2011 | 125 | 0.660 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 25 | 0.660 |
Why?
| | Intravitreal Injections | 10 | 2020 | 56 | 0.660 |
Why?
| | Peptide Fragments | 4 | 2013 | 706 | 0.660 |
Why?
| | Bleomycin | 3 | 2018 | 248 | 0.660 |
Why?
| | Molecular Chaperones | 3 | 2022 | 195 | 0.660 |
Why?
| | Injections, Intraocular | 3 | 2017 | 10 | 0.650 |
Why?
| | Antihypertensive Agents | 2 | 2014 | 494 | 0.630 |
Why?
| | beta-Cyclodextrins | 3 | 2004 | 28 | 0.630 |
Why?
| | Fluorescent Dyes | 5 | 2018 | 321 | 0.620 |
Why?
| | Genetic Therapy | 5 | 2014 | 297 | 0.610 |
Why?
| | Macular Degeneration | 5 | 2017 | 164 | 0.610 |
Why?
| | Ephrin-A2 | 1 | 2018 | 4 | 0.610 |
Why?
| | Albumins | 2 | 2019 | 114 | 0.610 |
Why?
| | Microscopy, Confocal | 8 | 2020 | 325 | 0.610 |
Why?
| | Lung Injury | 2 | 2018 | 219 | 0.610 |
Why?
| | Retinal Diseases | 5 | 2014 | 91 | 0.590 |
Why?
| | Cell Line | 17 | 2018 | 2847 | 0.580 |
Why?
| | Biological Transport | 9 | 2012 | 418 | 0.580 |
Why?
| | Mitochondria | 3 | 2022 | 948 | 0.580 |
Why?
| | Lipid Bilayers | 1 | 2019 | 98 | 0.580 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2013 | 804 | 0.580 |
Why?
| | Biological Availability | 9 | 2020 | 148 | 0.570 |
Why?
| | Lung | 5 | 2018 | 4060 | 0.570 |
Why?
| | Chromatography, High Pressure Liquid | 12 | 2013 | 597 | 0.570 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 107 | 0.570 |
Why?
| | Fluorescein-5-isothiocyanate | 4 | 2016 | 35 | 0.560 |
Why?
| | Thiophenes | 2 | 2025 | 117 | 0.560 |
Why?
| | Microspheres | 4 | 2012 | 137 | 0.550 |
Why?
| | Fluorescein | 4 | 2018 | 25 | 0.550 |
Why?
| | Needles | 1 | 2017 | 59 | 0.550 |
Why?
| | Area Under Curve | 7 | 2020 | 314 | 0.540 |
Why?
| | Permeability | 9 | 2018 | 161 | 0.540 |
Why?
| | Technology, Pharmaceutical | 2 | 2010 | 30 | 0.540 |
Why?
| | Retinitis Pigmentosa | 2 | 2014 | 20 | 0.520 |
Why?
| | Rats, Inbred BN | 8 | 2011 | 58 | 0.520 |
Why?
| | Cataract | 2 | 2011 | 213 | 0.510 |
Why?
| | Cephalosporins | 3 | 2002 | 48 | 0.490 |
Why?
| | Antineoplastic Agents | 6 | 2022 | 2129 | 0.490 |
Why?
| | Nanocapsules | 2 | 2013 | 14 | 0.490 |
Why?
| | Electric Impedance | 4 | 2014 | 107 | 0.480 |
Why?
| | Humans | 67 | 2025 | 137585 | 0.480 |
Why?
| | Dogs | 4 | 2025 | 413 | 0.470 |
Why?
| | Endothelial Cells | 3 | 2018 | 785 | 0.470 |
Why?
| | Dinoprostone | 3 | 2009 | 191 | 0.470 |
Why?
| | Epithelium, Corneal | 6 | 2018 | 41 | 0.470 |
Why?
| | Exfoliation Syndrome | 1 | 2014 | 10 | 0.460 |
Why?
| | RNA, Messenger | 16 | 2012 | 2833 | 0.460 |
Why?
| | Leukostasis | 2 | 2011 | 3 | 0.460 |
Why?
| | Pyridones | 2 | 2013 | 168 | 0.440 |
Why?
| | Disease Models, Animal | 15 | 2018 | 4295 | 0.430 |
Why?
| | Chemical Phenomena | 2 | 2011 | 83 | 0.430 |
Why?
| | Light | 2 | 2013 | 381 | 0.420 |
Why?
| | Chloroquine | 2 | 2012 | 54 | 0.410 |
Why?
| | Posterior Eye Segment | 1 | 2013 | 3 | 0.410 |
Why?
| | Transferrin | 3 | 2009 | 47 | 0.410 |
Why?
| | Serum Albumin, Bovine | 1 | 2013 | 64 | 0.410 |
Why?
| | Eye Proteins | 2 | 2012 | 92 | 0.410 |
Why?
| | Glaucoma, Open-Angle | 1 | 2014 | 103 | 0.400 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1242 | 0.400 |
Why?
| | Poloxamer | 2 | 2002 | 13 | 0.400 |
Why?
| | Cell Proliferation | 8 | 2017 | 2475 | 0.400 |
Why?
| | Salicylic Acid | 1 | 2012 | 10 | 0.400 |
Why?
| | Capsid Proteins | 1 | 2013 | 94 | 0.390 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.390 |
Why?
| | Nanomedicine | 1 | 2013 | 47 | 0.390 |
Why?
| | Phenylalanine | 1 | 2012 | 68 | 0.390 |
Why?
| | Fluocinolone Acetonide | 2 | 2011 | 19 | 0.390 |
Why?
| | Pyrimidines | 2 | 2017 | 470 | 0.390 |
Why?
| | Cyclooxygenase 2 | 4 | 2012 | 178 | 0.390 |
Why?
| | Mice | 23 | 2023 | 17787 | 0.380 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2011 | 323 | 0.380 |
Why?
| | Drug Implants | 3 | 2020 | 82 | 0.380 |
Why?
| | Chlorides | 4 | 1998 | 136 | 0.380 |
Why?
| | Geographic Atrophy | 1 | 2013 | 79 | 0.380 |
Why?
| | Pulmonary Fibrosis | 2 | 2013 | 402 | 0.380 |
Why?
| | Male | 44 | 2020 | 67762 | 0.380 |
Why?
| | Corneal Neovascularization | 4 | 2015 | 15 | 0.380 |
Why?
| | Bronchodilator Agents | 2 | 2005 | 252 | 0.370 |
Why?
| | Drug Liberation | 3 | 2021 | 35 | 0.370 |
Why?
| | Probenecid | 2 | 2009 | 8 | 0.370 |
Why?
| | Tyrosine | 1 | 2012 | 222 | 0.370 |
Why?
| | Injections | 8 | 2011 | 183 | 0.370 |
Why?
| | Adrenal Cortex Hormones | 3 | 2021 | 565 | 0.370 |
Why?
| | STAT1 Transcription Factor | 1 | 2011 | 72 | 0.360 |
Why?
| | Carbon Dioxide | 4 | 2013 | 267 | 0.360 |
Why?
| | Thiazines | 1 | 2011 | 10 | 0.360 |
Why?
| | Antioxidants | 2 | 2014 | 584 | 0.360 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 108 | 0.360 |
Why?
| | Macular Edema | 1 | 2011 | 43 | 0.350 |
Why?
| | Absorbable Implants | 2 | 2020 | 35 | 0.350 |
Why?
| | Bevacizumab | 4 | 2017 | 138 | 0.350 |
Why?
| | Mitochondrial Diseases | 1 | 2011 | 91 | 0.350 |
Why?
| | Oligonucleotides, Antisense | 3 | 2009 | 112 | 0.350 |
Why?
| | Polyglactin 910 | 2 | 2012 | 6 | 0.340 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 976 | 0.340 |
Why?
| | Oxidative Stress | 5 | 2021 | 1317 | 0.340 |
Why?
| | Poly G | 1 | 2010 | 2 | 0.340 |
Why?
| | Suspensions | 3 | 2020 | 36 | 0.340 |
Why?
| | Diclofenac | 2 | 2009 | 15 | 0.330 |
Why?
| | Trabecular Meshwork | 1 | 2011 | 79 | 0.330 |
Why?
| | Solvents | 5 | 2013 | 109 | 0.330 |
Why?
| | Vascular Endothelial Growth Factors | 6 | 2011 | 79 | 0.330 |
Why?
| | Micelles | 1 | 2010 | 39 | 0.330 |
Why?
| | Fluoroquinolones | 1 | 2010 | 51 | 0.330 |
Why?
| | Solubility | 5 | 2011 | 245 | 0.330 |
Why?
| | Vascular Diseases | 1 | 2012 | 243 | 0.330 |
Why?
| | Retinal Neovascularization | 4 | 2015 | 25 | 0.320 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2009 | 11 | 0.320 |
Why?
| | Drug Stability | 6 | 2011 | 167 | 0.320 |
Why?
| | Receptors, Glucocorticoid | 2 | 2009 | 155 | 0.310 |
Why?
| | Chorioallantoic Membrane | 1 | 2009 | 3 | 0.310 |
Why?
| | Gene Expression | 5 | 2018 | 1502 | 0.310 |
Why?
| | Porosity | 4 | 2013 | 102 | 0.310 |
Why?
| | Cell Survival | 6 | 2013 | 1120 | 0.300 |
Why?
| | Taxoids | 1 | 2009 | 102 | 0.300 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2008 | 19 | 0.300 |
Why?
| | Receptor, EphA2 | 2 | 2018 | 19 | 0.300 |
Why?
| | Plasmids | 5 | 2017 | 363 | 0.300 |
Why?
| | Endothelium, Corneal | 2 | 2021 | 16 | 0.290 |
Why?
| | Models, Animal | 2 | 2020 | 384 | 0.290 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 4 | 2010 | 86 | 0.290 |
Why?
| | Pharmacokinetics | 4 | 2012 | 29 | 0.290 |
Why?
| | Lung Neoplasms | 5 | 2017 | 2526 | 0.290 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 2057 | 0.290 |
Why?
| | Injections, Intravenous | 5 | 2017 | 206 | 0.290 |
Why?
| | Eye Color | 1 | 2008 | 3 | 0.290 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 390 | 0.290 |
Why?
| | Bruch Membrane | 2 | 2011 | 6 | 0.290 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 434 | 0.290 |
Why?
| | Retinal Pigments | 1 | 2007 | 6 | 0.280 |
Why?
| | Drug Administration Routes | 4 | 2009 | 38 | 0.280 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1502 | 0.280 |
Why?
| | Lasers | 3 | 2021 | 130 | 0.280 |
Why?
| | Anthraquinones | 1 | 2007 | 11 | 0.270 |
Why?
| | Chemistry, Pharmaceutical | 4 | 2012 | 105 | 0.270 |
Why?
| | Imidazolidines | 1 | 2007 | 10 | 0.270 |
Why?
| | Fluorophotometry | 2 | 2020 | 3 | 0.270 |
Why?
| | Indomethacin | 2 | 2004 | 81 | 0.270 |
Why?
| | Medical Oncology | 1 | 2009 | 289 | 0.270 |
Why?
| | ELAV-Like Protein 1 | 2 | 2017 | 16 | 0.260 |
Why?
| | Macula Lutea | 1 | 2007 | 21 | 0.260 |
Why?
| | Microscopy, Electron, Scanning | 5 | 2005 | 201 | 0.260 |
Why?
| | Rhodamines | 1 | 2006 | 20 | 0.260 |
Why?
| | Mannitol | 1 | 2006 | 38 | 0.260 |
Why?
| | DNA | 2 | 2013 | 1459 | 0.260 |
Why?
| | Serum Albumin | 1 | 2007 | 150 | 0.250 |
Why?
| | Blotting, Western | 7 | 2013 | 1226 | 0.250 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3284 | 0.250 |
Why?
| | Time Factors | 13 | 2015 | 6828 | 0.240 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2015 | 560 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 916 | 0.240 |
Why?
| | Aldehydes | 2 | 2005 | 145 | 0.240 |
Why?
| | Mites | 1 | 2025 | 7 | 0.230 |
Why?
| | Oxazoles | 1 | 2025 | 37 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 852 | 0.230 |
Why?
| | Superoxide Dismutase | 1 | 2007 | 346 | 0.230 |
Why?
| | Triamcinolone Acetonide | 3 | 2021 | 28 | 0.230 |
Why?
| | Swine | 5 | 2021 | 775 | 0.230 |
Why?
| | Cats | 1 | 2025 | 210 | 0.230 |
Why?
| | Buserelin | 1 | 2004 | 1 | 0.220 |
Why?
| | Glutathione | 2 | 2005 | 356 | 0.220 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2013 | 611 | 0.220 |
Why?
| | Oligopeptides | 3 | 2011 | 271 | 0.220 |
Why?
| | Orphan Nuclear Receptors | 3 | 2014 | 15 | 0.220 |
Why?
| | DNA Helicases | 2 | 2023 | 145 | 0.220 |
Why?
| | Cell Membrane Permeability | 4 | 2018 | 78 | 0.210 |
Why?
| | In Vitro Techniques | 6 | 2012 | 1092 | 0.210 |
Why?
| | Cell Line, Tumor | 7 | 2022 | 3412 | 0.210 |
Why?
| | Lysosomes | 2 | 2015 | 141 | 0.210 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2014 | 47 | 0.200 |
Why?
| | Half-Life | 3 | 2009 | 164 | 0.200 |
Why?
| | Mice, Inbred BALB C | 6 | 2014 | 1272 | 0.200 |
Why?
| | Circular Dichroism | 2 | 2013 | 149 | 0.200 |
Why?
| | Respiratory System | 1 | 2004 | 157 | 0.200 |
Why?
| | Cell Cycle | 3 | 2013 | 601 | 0.200 |
Why?
| | Octanols | 1 | 2022 | 1 | 0.200 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2002 | 49 | 0.190 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1167 | 0.190 |
Why?
| | Polyesters | 3 | 2013 | 76 | 0.190 |
Why?
| | Linear Models | 3 | 2009 | 849 | 0.190 |
Why?
| | Protein Structure, Secondary | 2 | 2013 | 374 | 0.190 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2002 | 38 | 0.190 |
Why?
| | alpha-Cyclodextrins | 1 | 2001 | 1 | 0.190 |
Why?
| | Protein Aggregates | 1 | 2022 | 72 | 0.190 |
Why?
| | Thiazolidinediones | 2 | 2013 | 137 | 0.190 |
Why?
| | Cyclodextrins | 1 | 2001 | 7 | 0.190 |
Why?
| | Liposomes | 3 | 2011 | 223 | 0.190 |
Why?
| | Transfection | 3 | 2015 | 945 | 0.190 |
Why?
| | Chymotrypsin | 1 | 2001 | 22 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 4 | 2017 | 184 | 0.180 |
Why?
| | Rhodopsin | 2 | 2011 | 11 | 0.180 |
Why?
| | Temperature | 5 | 2004 | 679 | 0.180 |
Why?
| | Electroretinography | 4 | 2018 | 48 | 0.180 |
Why?
| | Cystinosis | 1 | 2021 | 1 | 0.180 |
Why?
| | Biocompatible Materials | 2 | 2020 | 425 | 0.180 |
Why?
| | Contact Lenses | 1 | 2021 | 9 | 0.180 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 1043 | 0.180 |
Why?
| | Cystine | 1 | 2021 | 18 | 0.180 |
Why?
| | Models, Molecular | 2 | 2019 | 1570 | 0.180 |
Why?
| | Zinc Compounds | 2 | 1998 | 7 | 0.180 |
Why?
| | Brain | 2 | 2011 | 2668 | 0.180 |
Why?
| | Edetic Acid | 2 | 1998 | 50 | 0.180 |
Why?
| | Carboplatin | 2 | 2013 | 144 | 0.170 |
Why?
| | Oncogenes | 2 | 2022 | 116 | 0.170 |
Why?
| | Eye Burns | 2 | 2013 | 12 | 0.170 |
Why?
| | Fluorescein Angiography | 4 | 2017 | 151 | 0.170 |
Why?
| | Hypromellose Derivatives | 1 | 2020 | 1 | 0.170 |
Why?
| | Molecular Weight | 2 | 2013 | 335 | 0.170 |
Why?
| | Therapeutic Equivalency | 1 | 2020 | 32 | 0.170 |
Why?
| | Uveitis | 2 | 2014 | 136 | 0.170 |
Why?
| | Proteins | 2 | 2001 | 1009 | 0.170 |
Why?
| | Cytoskeleton | 1 | 2021 | 191 | 0.170 |
Why?
| | Mice, Nude | 3 | 2017 | 698 | 0.170 |
Why?
| | Collagen | 2 | 2013 | 452 | 0.170 |
Why?
| | Respiratory Mucosa | 1 | 2003 | 321 | 0.170 |
Why?
| | Symporters | 1 | 2020 | 66 | 0.170 |
Why?
| | Corneal Stroma | 2 | 2018 | 23 | 0.170 |
Why?
| | Prodrugs | 1 | 2000 | 52 | 0.160 |
Why?
| | Cholic Acids | 2 | 2011 | 18 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 71 | 0.160 |
Why?
| | Ophthalmology | 1 | 2021 | 86 | 0.160 |
Why?
| | Benzo(a)pyrene | 2 | 2013 | 8 | 0.160 |
Why?
| | Pyramidal Cells | 1 | 2020 | 74 | 0.160 |
Why?
| | Administration, Oral | 3 | 2012 | 816 | 0.160 |
Why?
| | 2-Hydroxypropyl-beta-cyclodextrin | 3 | 2004 | 7 | 0.160 |
Why?
| | Body Weight | 3 | 2011 | 985 | 0.160 |
Why?
| | Thermodynamics | 1 | 2001 | 407 | 0.160 |
Why?
| | Prednisolone | 2 | 2011 | 83 | 0.160 |
Why?
| | Gene Expression Regulation | 6 | 2018 | 2607 | 0.150 |
Why?
| | Synovial Fluid | 1 | 1999 | 68 | 0.150 |
Why?
| | Adsorption | 1 | 2019 | 149 | 0.150 |
Why?
| | Chitosan | 2 | 2016 | 34 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2020 | 218 | 0.150 |
Why?
| | Molecular Targeted Therapy | 2 | 2011 | 411 | 0.150 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 786 | 0.140 |
Why?
| | Models, Biological | 3 | 2013 | 1783 | 0.140 |
Why?
| | Chemistry, Physical | 2 | 2009 | 37 | 0.140 |
Why?
| | Surface Properties | 1 | 2019 | 413 | 0.140 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 301 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2018 | 4193 | 0.140 |
Why?
| | Gene Silencing | 3 | 2017 | 195 | 0.140 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 110 | 0.140 |
Why?
| | Mice, Inbred C57BL | 8 | 2018 | 5757 | 0.140 |
Why?
| | Drug Interactions | 3 | 2013 | 410 | 0.140 |
Why?
| | Regional Blood Flow | 2 | 2011 | 474 | 0.140 |
Why?
| | Molecular Structure | 2 | 2009 | 489 | 0.140 |
Why?
| | Endoplasmic Reticulum | 2 | 2018 | 265 | 0.140 |
Why?
| | Glioma | 1 | 2022 | 395 | 0.140 |
Why?
| | Glycoproteins | 1 | 1999 | 342 | 0.140 |
Why?
| | Drug Combinations | 2 | 2011 | 343 | 0.140 |
Why?
| | Action Potentials | 1 | 2020 | 493 | 0.130 |
Why?
| | Excipients | 2 | 2001 | 55 | 0.130 |
Why?
| | Turbinates | 2 | 2008 | 14 | 0.130 |
Why?
| | RNAi Therapeutics | 1 | 2016 | 6 | 0.130 |
Why?
| | Dextran Sulfate | 1 | 2016 | 83 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2013 | 652 | 0.130 |
Why?
| | Mifepristone | 2 | 2009 | 64 | 0.130 |
Why?
| | Folate Receptor 1 | 1 | 2016 | 15 | 0.130 |
Why?
| | 2,4-Dinitrophenol | 3 | 2004 | 9 | 0.130 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 48 | 0.120 |
Why?
| | Surgeons | 1 | 2020 | 297 | 0.120 |
Why?
| | Immunoconjugates | 1 | 2017 | 114 | 0.120 |
Why?
| | Transient Receptor Potential Channels | 1 | 2015 | 4 | 0.120 |
Why?
| | Central Nervous System | 1 | 1998 | 258 | 0.120 |
Why?
| | Indazoles | 2 | 2017 | 69 | 0.120 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2015 | 16 | 0.120 |
Why?
| | Presenilin-1 | 1 | 2015 | 31 | 0.120 |
Why?
| | Signal Transduction | 2 | 2013 | 5079 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 429 | 0.120 |
Why?
| | Wnt3A Protein | 1 | 2015 | 10 | 0.120 |
Why?
| | Hippocampus | 1 | 2020 | 895 | 0.120 |
Why?
| | Receptors, LDL | 1 | 2015 | 47 | 0.120 |
Why?
| | Cyclic AMP | 1 | 1996 | 234 | 0.120 |
Why?
| | Mucous Membrane | 3 | 1996 | 125 | 0.110 |
Why?
| | Absorption | 2 | 2004 | 63 | 0.110 |
Why?
| | Female | 16 | 2020 | 73304 | 0.110 |
Why?
| | Sodium | 2 | 1996 | 217 | 0.110 |
Why?
| | Administration, Intranasal | 2 | 2009 | 90 | 0.110 |
Why?
| | Vaccine Potency | 1 | 2014 | 6 | 0.110 |
Why?
| | Retinal Vessels | 1 | 2015 | 69 | 0.110 |
Why?
| | Aluminum Hydroxide | 1 | 2014 | 12 | 0.110 |
Why?
| | Injections, Intraperitoneal | 2 | 2004 | 114 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.110 |
Why?
| | Plasminogen | 2 | 2011 | 30 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2014 | 346 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 2 | 2010 | 361 | 0.110 |
Why?
| | Phagocytosis | 2 | 2013 | 380 | 0.110 |
Why?
| | Eye Diseases, Hereditary | 1 | 2014 | 12 | 0.110 |
Why?
| | Hepatitis B Vaccines | 1 | 2014 | 45 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 90 | 0.110 |
Why?
| | Blood Glucose | 3 | 2011 | 2186 | 0.110 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 77 | 0.110 |
Why?
| | Acetophenones | 1 | 2013 | 13 | 0.110 |
Why?
| | Tight Junctions | 1 | 2014 | 76 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2014 | 132 | 0.100 |
Why?
| | Fibrosis | 2 | 2013 | 552 | 0.100 |
Why?
| | Withanolides | 1 | 2013 | 3 | 0.100 |
Why?
| | Calorimetry, Differential Scanning | 2 | 2004 | 37 | 0.100 |
Why?
| | Micro-Electrical-Mechanical Systems | 1 | 2013 | 5 | 0.100 |
Why?
| | Chromatography, Gel | 1 | 2013 | 127 | 0.100 |
Why?
| | Cholesterol | 2 | 2016 | 410 | 0.100 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2013 | 17 | 0.100 |
Why?
| | Cell Shape | 1 | 2013 | 57 | 0.100 |
Why?
| | alpha-Crystallin A Chain | 1 | 2013 | 13 | 0.100 |
Why?
| | Gemfibrozil | 1 | 2013 | 11 | 0.100 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 122 | 0.100 |
Why?
| | Trachea | 2 | 2005 | 237 | 0.100 |
Why?
| | Capsid | 1 | 2013 | 93 | 0.100 |
Why?
| | Scattering, Radiation | 1 | 2013 | 101 | 0.100 |
Why?
| | Monophenol Monooxygenase | 1 | 2012 | 8 | 0.100 |
Why?
| | Vimentin | 1 | 2013 | 52 | 0.100 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2012 | 14 | 0.100 |
Why?
| | Receptors, Transferrin | 2 | 2017 | 24 | 0.100 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 192 | 0.100 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 144 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2014 | 226 | 0.100 |
Why?
| | Corneal Injuries | 1 | 2013 | 44 | 0.100 |
Why?
| | Pressure | 1 | 2013 | 225 | 0.100 |
Why?
| | Levodopa | 1 | 2012 | 30 | 0.100 |
Why?
| | Timolol | 2 | 2011 | 14 | 0.100 |
Why?
| | Bronchoalveolar Lavage | 1 | 2012 | 93 | 0.100 |
Why?
| | Gels | 2 | 2002 | 80 | 0.100 |
Why?
| | Protein Stability | 1 | 2013 | 176 | 0.100 |
Why?
| | Vision Disorders | 1 | 2014 | 142 | 0.100 |
Why?
| | Ouabain | 3 | 1998 | 16 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2014 | 10811 | 0.100 |
Why?
| | Cell Count | 1 | 2013 | 324 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1946 | 0.100 |
Why?
| | Colorimetry | 1 | 2012 | 12 | 0.100 |
Why?
| | Pigmentation | 1 | 2012 | 52 | 0.100 |
Why?
| | Corneal Diseases | 1 | 2012 | 35 | 0.100 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.100 |
Why?
| | Doxycycline | 1 | 2012 | 62 | 0.100 |
Why?
| | Hypolipidemic Agents | 1 | 2013 | 91 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.100 |
Why?
| | Macaca fascicularis | 1 | 2012 | 65 | 0.090 |
Why?
| | Aqueous Humor | 2 | 2014 | 34 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2013 | 534 | 0.090 |
Why?
| | Swine, Miniature | 1 | 2012 | 82 | 0.090 |
Why?
| | Membrane Transport Proteins | 1 | 2013 | 162 | 0.090 |
Why?
| | Paclitaxel | 1 | 2013 | 230 | 0.090 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2011 | 18 | 0.090 |
Why?
| | Apoptosis | 4 | 2013 | 2553 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 927 | 0.090 |
Why?
| | Inflammation | 2 | 2020 | 2837 | 0.090 |
Why?
| | Computer Simulation | 2 | 2018 | 978 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 142 | 0.090 |
Why?
| | MicroRNAs | 1 | 2018 | 692 | 0.090 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2011 | 14 | 0.090 |
Why?
| | Propranolol | 1 | 2011 | 50 | 0.090 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2011 | 72 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 872 | 0.090 |
Why?
| | Carbon | 1 | 2012 | 216 | 0.090 |
Why?
| | Quinoxalines | 1 | 2011 | 66 | 0.090 |
Why?
| | Optic Nerve | 1 | 2011 | 64 | 0.090 |
Why?
| | Curcumin | 1 | 2011 | 29 | 0.090 |
Why?
| | Amino Acids | 1 | 1995 | 497 | 0.090 |
Why?
| | Diffusion Chambers, Culture | 2 | 2010 | 9 | 0.090 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 77 | 0.090 |
Why?
| | Chemical Warfare Agents | 1 | 2012 | 114 | 0.090 |
Why?
| | Biological Transport, Active | 4 | 2010 | 77 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2013 | 730 | 0.090 |
Why?
| | Materials Testing | 1 | 2012 | 356 | 0.090 |
Why?
| | Rats, Wistar | 1 | 2012 | 455 | 0.090 |
Why?
| | Silymarin | 1 | 2012 | 199 | 0.090 |
Why?
| | Ion Transport | 3 | 1996 | 60 | 0.090 |
Why?
| | Gold | 2 | 2022 | 118 | 0.090 |
Why?
| | Lipogenesis | 1 | 2011 | 61 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2012 | 1809 | 0.080 |
Why?
| | Wound Healing | 1 | 2013 | 331 | 0.080 |
Why?
| | Pregnadienediols | 1 | 2010 | 4 | 0.080 |
Why?
| | Chromatography, Supercritical Fluid | 1 | 2009 | 3 | 0.080 |
Why?
| | Calorimetry | 1 | 2010 | 70 | 0.080 |
Why?
| | Leukocytes | 1 | 2011 | 311 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5472 | 0.080 |
Why?
| | Emulsions | 1 | 2009 | 53 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2011 | 302 | 0.080 |
Why?
| | Stress, Physiological | 1 | 2013 | 443 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 660 | 0.080 |
Why?
| | Dosage Forms | 1 | 2009 | 11 | 0.080 |
Why?
| | Blood Proteins | 1 | 2011 | 252 | 0.080 |
Why?
| | Graft Survival | 1 | 2012 | 535 | 0.080 |
Why?
| | Retinal Neoplasms | 1 | 2009 | 25 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2012 | 1178 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1199 | 0.080 |
Why?
| | Neoplasm Transplantation | 1 | 2009 | 257 | 0.080 |
Why?
| | Retinoblastoma | 1 | 2009 | 32 | 0.080 |
Why?
| | Chick Embryo | 1 | 2009 | 130 | 0.080 |
Why?
| | Genetic Vectors | 2 | 2007 | 319 | 0.080 |
Why?
| | Anticholesteremic Agents | 1 | 2011 | 153 | 0.080 |
Why?
| | Vinblastine | 1 | 2009 | 71 | 0.080 |
Why?
| | Cell Membrane | 1 | 2012 | 738 | 0.080 |
Why?
| | Least-Squares Analysis | 1 | 2008 | 79 | 0.080 |
Why?
| | Aging | 1 | 2019 | 1864 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2671 | 0.070 |
Why?
| | Drug Synergism | 1 | 2009 | 382 | 0.070 |
Why?
| | Calibration | 1 | 2008 | 146 | 0.070 |
Why?
| | Validation Studies as Topic | 1 | 2008 | 22 | 0.070 |
Why?
| | Tumor Burden | 1 | 2009 | 309 | 0.070 |
Why?
| | Thionucleotides | 1 | 2007 | 35 | 0.070 |
Why?
| | Tosylphenylalanyl Chloromethyl Ketone | 2 | 1998 | 3 | 0.070 |
Why?
| | Ethylmaleimide | 2 | 1998 | 18 | 0.070 |
Why?
| | Neovascularization, Physiologic | 1 | 2009 | 179 | 0.070 |
Why?
| | Mice, Transgenic | 4 | 2018 | 2167 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 322 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 106 | 0.070 |
Why?
| | Caveolae | 1 | 2007 | 18 | 0.070 |
Why?
| | Cell Movement | 3 | 2017 | 967 | 0.070 |
Why?
| | Models, Anatomic | 1 | 2008 | 93 | 0.070 |
Why?
| | Clathrin | 1 | 2007 | 27 | 0.070 |
Why?
| | Pharmaceutical Vehicles | 1 | 2007 | 12 | 0.070 |
Why?
| | Species Specificity | 1 | 2008 | 585 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 518 | 0.070 |
Why?
| | Glycopeptides | 2 | 1998 | 43 | 0.070 |
Why?
| | Mydriasis | 1 | 2007 | 10 | 0.070 |
Why?
| | Cells | 1 | 2007 | 25 | 0.070 |
Why?
| | Galactose | 1 | 2007 | 33 | 0.070 |
Why?
| | Vacuoles | 1 | 2007 | 40 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 234 | 0.070 |
Why?
| | Doxorubicin | 1 | 2009 | 362 | 0.070 |
Why?
| | Burns, Chemical | 1 | 2007 | 32 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2009 | 405 | 0.070 |
Why?
| | Aptamers, Nucleotide | 1 | 2007 | 83 | 0.060 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 220 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2007 | 166 | 0.060 |
Why?
| | Diffusion | 2 | 2009 | 116 | 0.060 |
Why?
| | Ketorolac Tromethamine | 1 | 2006 | 3 | 0.060 |
Why?
| | Macrophages | 2 | 2011 | 1547 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2007 | 226 | 0.060 |
Why?
| | Software | 1 | 2011 | 665 | 0.060 |
Why?
| | Electrophysiology | 3 | 1996 | 217 | 0.060 |
Why?
| | Mass Spectrometry | 1 | 2009 | 739 | 0.060 |
Why?
| | Alzheimer Disease | 1 | 2011 | 560 | 0.060 |
Why?
| | Thiobarbituric Acid Reactive Substances | 1 | 2005 | 30 | 0.060 |
Why?
| | Glutathione Disulfide | 1 | 2005 | 33 | 0.060 |
Why?
| | Hydrogels | 1 | 2012 | 678 | 0.060 |
Why?
| | Lymph Nodes | 1 | 2008 | 491 | 0.060 |
Why?
| | Dextrans | 2 | 2016 | 84 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2005 | 129 | 0.060 |
Why?
| | Cyclooxygenase 1 | 1 | 2004 | 27 | 0.060 |
Why?
| | Kidney | 1 | 2012 | 1468 | 0.060 |
Why?
| | Carcinogens | 1 | 2005 | 125 | 0.060 |
Why?
| | Oligoribonucleotides, Antisense | 1 | 2004 | 3 | 0.060 |
Why?
| | Pharmaceutical Solutions | 1 | 2004 | 14 | 0.060 |
Why?
| | Powders | 1 | 2004 | 43 | 0.060 |
Why?
| | X-Ray Diffraction | 1 | 2004 | 104 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2008 | 415 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2013 | 1738 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1430 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2007 | 620 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1692 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1291 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 363 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 390 | 0.050 |
Why?
| | Cytochrome P-450 CYP2C8 | 2 | 2013 | 15 | 0.050 |
Why?
| | Hormone Antagonists | 1 | 2003 | 34 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2031 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1040 | 0.050 |
Why?
| | Cytosol | 1 | 2003 | 226 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2004 | 688 | 0.050 |
Why?
| | Theranostic Nanomedicine | 1 | 2022 | 15 | 0.050 |
Why?
| | Flow Injection Analysis | 1 | 2002 | 6 | 0.050 |
Why?
| | Dialysis | 1 | 2002 | 20 | 0.050 |
Why?
| | Fuchs' Endothelial Dystrophy | 1 | 2021 | 1 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2002 | 153 | 0.050 |
Why?
| | Verapamil | 1 | 2002 | 41 | 0.050 |
Why?
| | Indocyanine Green | 1 | 2022 | 24 | 0.050 |
Why?
| | Chemical Precipitation | 1 | 2002 | 37 | 0.050 |
Why?
| | Amino Acids, Aromatic | 1 | 2001 | 7 | 0.050 |
Why?
| | Isoenzymes | 1 | 2003 | 304 | 0.050 |
Why?
| | Phototherapy | 1 | 2022 | 39 | 0.050 |
Why?
| | Capsules | 1 | 2002 | 38 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1793 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2007 | 744 | 0.050 |
Why?
| | Vincristine | 1 | 2002 | 116 | 0.050 |
Why?
| | Tetrazolium Salts | 1 | 2001 | 17 | 0.050 |
Why?
| | Solutions | 1 | 2002 | 168 | 0.040 |
Why?
| | Antimetabolites | 1 | 2001 | 23 | 0.040 |
Why?
| | Indicators and Reagents | 1 | 2001 | 106 | 0.040 |
Why?
| | Spectrometry, Fluorescence | 1 | 2001 | 168 | 0.040 |
Why?
| | Drug Design | 1 | 2022 | 167 | 0.040 |
Why?
| | Thiazoles | 1 | 2001 | 123 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 283 | 0.040 |
Why?
| | Middle Aged | 5 | 2018 | 33479 | 0.040 |
Why?
| | Metal Nanoparticles | 1 | 2021 | 83 | 0.040 |
Why?
| | Hydrolysis | 1 | 2000 | 177 | 0.040 |
Why?
| | Ascorbic Acid | 1 | 2021 | 177 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 217 | 0.040 |
Why?
| | Liver X Receptors | 2 | 2011 | 31 | 0.040 |
Why?
| | Cold Temperature | 1 | 2001 | 179 | 0.040 |
Why?
| | Bronchi | 1 | 2001 | 260 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2001 | 955 | 0.040 |
Why?
| | Stereoisomerism | 1 | 1999 | 96 | 0.040 |
Why?
| | Mannheimia haemolytica | 1 | 1999 | 1 | 0.040 |
Why?
| | Microtubules | 1 | 2021 | 279 | 0.040 |
Why?
| | Receptor, TIE-2 | 1 | 2018 | 12 | 0.040 |
Why?
| | Instillation, Drug | 1 | 2018 | 10 | 0.040 |
Why?
| | Fluorometry | 1 | 2018 | 17 | 0.040 |
Why?
| | Streptozocin | 1 | 2018 | 21 | 0.040 |
Why?
| | Tears | 1 | 2018 | 28 | 0.040 |
Why?
| | Protein Conformation | 1 | 2001 | 934 | 0.040 |
Why?
| | Dithiothreitol | 1 | 1998 | 17 | 0.040 |
Why?
| | Random Allocation | 1 | 1999 | 353 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2018 | 148 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2004 | 1164 | 0.040 |
Why?
| | Olfactory Pathways | 1 | 1998 | 36 | 0.040 |
Why?
| | Electroencephalography | 1 | 2020 | 423 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 127 | 0.030 |
Why?
| | Protein Binding | 1 | 2004 | 2224 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 1998 | 92 | 0.030 |
Why?
| | G1 Phase | 1 | 2017 | 71 | 0.030 |
Why?
| | Fatty Liver | 2 | 2011 | 243 | 0.030 |
Why?
| | Static Electricity | 1 | 2017 | 118 | 0.030 |
Why?
| | Seizures | 1 | 2020 | 426 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2017 | 98 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2017 | 173 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1997 | 107 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2016 | 150 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 327 | 0.030 |
Why?
| | Terbutaline | 1 | 1996 | 8 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 51 | 0.030 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 21 | 0.030 |
Why?
| | Colforsin | 1 | 1996 | 53 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 171 | 0.030 |
Why?
| | Visual Acuity | 1 | 2018 | 356 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 209 | 0.030 |
Why?
| | Theophylline | 1 | 1996 | 67 | 0.030 |
Why?
| | Endocytosis | 1 | 2016 | 172 | 0.030 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 1996 | 89 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1316 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2015 | 4 | 0.030 |
Why?
| | Epinephrine | 1 | 1996 | 139 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1996 | 134 | 0.030 |
Why?
| | Folic Acid | 1 | 2016 | 186 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 167 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 177 | 0.030 |
Why?
| | Hemoglobins | 1 | 2017 | 353 | 0.030 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2014 | 24 | 0.030 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2014 | 16 | 0.030 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2014 | 15 | 0.030 |
Why?
| | Cycloheximide | 1 | 2014 | 55 | 0.030 |
Why?
| | ortho-Aminobenzoates | 1 | 1993 | 10 | 0.030 |
Why?
| | Barium Compounds | 1 | 1993 | 8 | 0.030 |
Why?
| | Chloride Channels | 1 | 1993 | 35 | 0.030 |
Why?
| | Tenon Capsule | 1 | 2013 | 3 | 0.030 |
Why?
| | Fundus Oculi | 1 | 2013 | 65 | 0.030 |
Why?
| | Diuretics | 1 | 1993 | 74 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2013 | 20 | 0.030 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2013 | 51 | 0.030 |
Why?
| | Ion Channels | 1 | 1993 | 133 | 0.030 |
Why?
| | Arginine | 1 | 1995 | 271 | 0.030 |
Why?
| | Pepstatins | 1 | 2012 | 4 | 0.030 |
Why?
| | Lipofuscin | 1 | 2012 | 3 | 0.030 |
Why?
| | Haplorhini | 1 | 2013 | 52 | 0.030 |
Why?
| | Cathepsin D | 1 | 2012 | 18 | 0.030 |
Why?
| | Opsins | 1 | 2012 | 10 | 0.030 |
Why?
| | RNA Interference | 1 | 2015 | 469 | 0.030 |
Why?
| | Autophagy | 1 | 2015 | 284 | 0.020 |
Why?
| | Antibody Formation | 1 | 2014 | 298 | 0.020 |
Why?
| | Boron Compounds | 1 | 2012 | 27 | 0.020 |
Why?
| | beta Catenin | 1 | 2015 | 253 | 0.020 |
Why?
| | Glaucoma Drainage Implants | 1 | 2013 | 46 | 0.020 |
Why?
| | Oxidants | 1 | 2013 | 111 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2013 | 188 | 0.020 |
Why?
| | Irritants | 1 | 2012 | 43 | 0.020 |
Why?
| | Immunoblotting | 1 | 2012 | 308 | 0.020 |
Why?
| | Caspase 3 | 1 | 2013 | 246 | 0.020 |
Why?
| | Mechlorethamine | 1 | 2012 | 60 | 0.020 |
Why?
| | Catalytic Domain | 1 | 2012 | 207 | 0.020 |
Why?
| | Brimonidine Tartrate | 1 | 2011 | 10 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2013 | 175 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 861 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 2139 | 0.020 |
Why?
| | Rats, Transgenic | 1 | 2011 | 19 | 0.020 |
Why?
| | Homeostasis | 1 | 2015 | 621 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2013 | 328 | 0.020 |
Why?
| | Desmosterol | 1 | 2011 | 1 | 0.020 |
Why?
| | Androstenes | 1 | 2011 | 18 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1996 | 2900 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 115 | 0.020 |
Why?
| | COS Cells | 1 | 2011 | 188 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2011 | 139 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2011 | 67 | 0.020 |
Why?
| | Mustard Gas | 1 | 2012 | 103 | 0.020 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 26 | 0.020 |
Why?
| | Laser Coagulation | 1 | 2011 | 68 | 0.020 |
Why?
| | Adult | 4 | 2018 | 37929 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 402 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 1991 | 102 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 375 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 564 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1759 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 1396 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2014 | 625 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2014 | 893 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1353 | 0.020 |
Why?
| | Ketorolac | 1 | 2009 | 20 | 0.020 |
Why?
| | RNA, Ribosomal, 18S | 1 | 2009 | 26 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2010 | 284 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1066 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 13209 | 0.020 |
Why?
| | Gene Amplification | 1 | 2009 | 104 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2008 | 10 | 0.020 |
Why?
| | Foam Cells | 1 | 2008 | 18 | 0.020 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 57 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 39 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2008 | 83 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 515 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1062 | 0.020 |
Why?
| | Fibroblasts | 1 | 2013 | 996 | 0.020 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2008 | 137 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3015 | 0.020 |
Why?
| | Intestines | 1 | 2011 | 357 | 0.020 |
Why?
| | Feces | 1 | 2011 | 484 | 0.020 |
Why?
| | Sodium Hydroxide | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptors, Peptide | 1 | 2007 | 17 | 0.020 |
Why?
| | Cell Fractionation | 1 | 2007 | 56 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2011 | 596 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2010 | 578 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 157 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 641 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 886 | 0.020 |
Why?
| | Biomedical Research | 1 | 2010 | 692 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2828 | 0.010 |
Why?
| | Phlorhizin | 1 | 1996 | 2 | 0.010 |
Why?
| | Phloretin | 1 | 1996 | 2 | 0.010 |
Why?
| | Levobunolol | 1 | 1993 | 1 | 0.010 |
Why?
| | Betaxolol | 1 | 1993 | 2 | 0.010 |
Why?
| | Atenolol | 1 | 1993 | 7 | 0.010 |
Why?
| | Nasolacrimal Duct | 1 | 1993 | 8 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1670 | 0.010 |
Why?
| | Glucose | 1 | 1996 | 1020 | 0.010 |
Why?
| | Aged | 1 | 2009 | 23961 | 0.000 |
Why?
|
|
Kompella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|